Global Bacteriophages Therapy Market (Targeted Bacteria (Escherichia coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, Others), By Route of Administration (Oral, Topical, Parenteral), By Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), By End User(Hospitals & Clinics, Academic Research Organizations & Institutes and Others)) – Prospective Landscape, Size, Share, Growth, Opportunities and Industry Forecast 2019-2028

Published DateReport CodeNo. of PagesReport Format
April– 2021AMR- 12008110PDF / Excel
  • The bacteriophages therapy market was valued at US$ XX million in 2019 and anticipated to grow at a CAGR of 17.1% throughout the forecast period to reach over US$ XX million by 2028.

SelectLicense Type

Market Insights

The bacteriophages therapy market was valued at US$ XX million in 2019 and anticipated to grow at a CAGR of 17.1% throughout the forecast period to reach over US$ XX million by 2028. The rising demand for bacteriophages therapy in the emerging economies owing to the increasing foodborne diseases in the developing economies such as India, China, and others. Moreover, the growing research & development activities worldwide along with the increased mergers & acquisitions and collaborations among key players are the major factors for the growth of the global bacteriophages therapy market over the upcoming years. For instance, in May 2019, Mount Sinai Hospital, New York and Intralytix Inc. collaborated to initiate phase ½ clinical trial to evaluate efficacy of Ecoactive and safety for the patients of inactive Crohn’s disease.

 

Market Trends

The use of bacteriophage therapy for COVID-19 patients is one of the leading trends which are observed in the global bacteriophages therapy market. In November 2020, the Food and Drug Administration (FDA) has given Adaptive Phage Therapeutics a green light to Expanded Access IND to use of phage therapy for COVID19 patients who are in a critical state. Bacterial infections as a result of secondary infection due to COVID19 has left patients facing the battle against antibiotic resistance. The majority of bacteria are those that cause pneumonia and sepsis.

 

Market Drivers

The major factors which are driving the growth of the global bacteriophages therapy market are the growing foodborne diseases along with the increased collaborations among hospitals, research institutes, and major players for the development of bacteriophage therapy. For instance, in June 2020, Intralytix, Inc. announced that the company had entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Soldier Center (CCDC SC) in Natick, Massachusetts. The CRADA will focus on developing a dehydration process for bacteriophage cocktails, for use as a non-chemical and environmentally friendly food safety intervention and mitigation strategy for bacterial pathogens in fresh military procured food items.

 

Market Challenges

 

The bacteriophages therapy market challenges are the high cost of bacteriophage therapy and lack of skilled professionals are anticipated to hinder the market growth in the years to come. Moreover, the expensive testing and high product failure risk for drug development are further anticipated to hamper the market growth.

 

Segment Insights

Based on end-user, the global bacteriophages therapy market is categorized into hospitals and clinics, academic research organizations & institutes and others. In 2019, the hospitals and clinics category accounted for the significant share in the global market. This is majorly due to the increased cases of foodborne diseases worldwide along with the growing investments for advanced healthcare infrastructure across the globe.

 

Regional Insights

North America accounted for the largest share in the global bacteriophages therapy market in 2019 and had over 40% of the market revenue share in the same year. The region had its dominance due to the rising foodborne diseases and the presence of key market players such as Armata Pharmaceuticals, Inc., Phage International, Inc., and iNtODEWORLD, Inc. among others. Moreover, the growing collaborations and mergers among major players is another key factor for the growth of the regional market. Moreover, the U.S. had a major share in the North American bacteriophages therapy market in 2019 and is projected to continue its dominant position worldwide.

 

Besides, Asia Pacific is estimated to witness the fastest growth in the global bacteriophages therapy market in the years to come. This is ascribed to the growing antimicrobial resistance along with the rising foodborne diseases in the region. Furthermore, the increased product launches in Asia Pacific is another key factor for the growth of the market in the region.

 

Top Companies with Recent Development

 

Noticeable players within the Market

 

  • Armata Pharmaceuticals, Inc.,
  • iNtODEWORLD, Inc,
  • Phage International, Inc,
  • Fixed-Phage Limited,
  • LOCUS BIOSCIENCES, INC.,
  • Pherecydes Pharma,
  • Adaptive Phage Therapeutics, Inc.,
  • Intralytix, Phagelux, Inc.,
  • PhagoMed Biopharma GmbH,
  • ContraFect Corporation,
  • MICREOS,
  • Fixed-Phage Limited,
  • Phi Therapeutics.
  • BiomX,
  • Eligo Bioscience,
  • TechnoPhage,
  • Nextbiotics
  • Eliava Bio Preparations LTD

 

The above mentioned major players for the bacteriophages therapy market are investing heavily in Research & Development to introduce new products and offers along with enhanced technology to increase their market share and geographical expansion. Besides, the bacteriophages therapy market players are concentrating on various strategies such as technological innovations, geographical expansion, acquisitions, strategic collaboration, strategic contracts, new product launches, and mergers to increase their market presence. For instance, in January 2021, the first successful attempt at the creation of synthetic bacteriophages was achieved by scientists from the CEB – Centre of Biological Engineering, Universidade Do Minho, Braga in Portugal. The synthetic bacteriophages against Pseudomonas aeruginosa bacteria were created to contain a shortened genome. Researchers hope that this advancement may be the first step in creating a new antibacterial approach to the battle against the constantly evolving antibiotic-resistant threat.

 

Report Scope by Market Segments

 

This report splits the bacteriophages therapy market revenue opportunities worldwide, regional, and national levels and gives a comprehensive research study of the most recent industry activities in each of the sub-segments throughout the forecast period. For the reason of this ponder, Alchemy Market Research has segmented the bacteriophages therapy market report on the premise of product, application, route of administration, end user, and regional analysis:

 

By Targeted Bacteria

  • Escherichia Coli
  • Staphylococcus
  • Streptococcus
  • Pseudomonas
  • Salmonella
  • Others

By Application

  • Diagnostic
  • Antimicrobial Drug Discovery
  • Veterinary Medicines
  • Others

By Route of Administration

  • Oral
  • Topical
  • Parenteral

By End User

  • Hospitals
  • Academic Research Organizations & Institutes
  • Others

Regional Perspective

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia- Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Rest of the Middle East & Africa

This report answers key questions such as

  • What are the challenges in the bacteriophages therapy market?
  • What are the factors anticipated to drive the bacteriophages therapy market?
  • What are trends, restraints, and challenges in the bacteriophages therapy market?
  • Who are the potential customers of the bacteriophages therapy market?
  • Analysis of key strategies by key market players?
  • Which region is growing rapidly?
  • How do rapidly changing consumer perspectives will affect the bacteriophages therapy market?
  • How is the competitive environment?
  • Comprehensive details of factors that will challenge the growth of the market pre & post-COVID-19.
  • How are collaborations evolving in the market?
  • What is the customer sentiment about this market?
  • What are the solutions to the challenges?
  • What are the opportunities in this market?
  • What are the key current & upcoming technological trends estimated to drive the markets?
  • Regions & segment-wise analysis of how various industries will perform?
  • Forecasts on how market drivers, restraints, and future opportunities will affect market dynamics?

 Synopsis:

The bacteriophages therapy market is mainly driven by the growing foodborne diseases along with the rising prevalence of others diseases such as obesity, diabetes, cancer, and others. The bacteriophage therapy is also called phage therapy and uses viruses for the treatment of numerous bacterial infections. Moreover, the adoption of bacteriophages therapy for COVID-19 patients along with the growing product launches and acquisitions in the emerging economies are some other key factors for the growth of the global bacteriophages therapy market during the forecast period.  On account of the aforementioned factors, Alchemy Research & Analytics LLP, anticipated that the global bacteriophages therapy market will grow at a CAGR of 17.1% in the years to come.

Chapter 1. Executive Summary

Chapter 2. Market Introduction

Chapter 3. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – Key Industry Dynamics

3.1. Key Market Drivers
3.2. Key Market Restraints
3.3. Market Opportunities
3.4. Future Trends
3.5. Impact Analysis of Drivers and Restraints

Chapter 4. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Market Analysis Tools

4.1. Industry Analysis – Porter’s

4.1.1. Supplier Power
4.1.2. Buyer Power
4.1.3. Substitution Threat
4.1.4. Threat from New Entrants
4.1.5. Competitive Rivalry

4.2. Pestel Analysis

4.2.1. Political Landscape
4.2.2. Environmental Landscape
4.2.3. Social Landscape
4.2.4. Technology Landscape
4.2.5. Legal Landscape

4.3. Major Deals & Strategic Alliances Analysis

4.3.1. Joint Ventures
4.3.2. Mergers and Acquisitions
4.3.3. Licensing and Partnership
4.3.4. Technology Collaborations
4.3.5. Strategic Divestments

Chapter 5. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

Chapter 6. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Targeted Bacteria

6.1. Escherichia coli
6.2. Staphylococcus
6.3. Streptococcus
6.4. Pseudomonas
6.5. Salmonella
6.6. Others

Chapter 7. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Route of Administration

7.1. Oral
7.2. Topical
7.3. Parenteral

Chapter 8. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Application

8.1. Diagnostic
8.2. Antimicrobial Drug Discovery
8.3. Veterinary Medicines
8.4. Others

Chapter 9. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By End User

9.1. Hospitals & Clinics
9.2. Academic Research Organizations & Institutes
9.3. Others

Chapter 10. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Region

10.1. North America
10.2. Europe
10.3. Asia-Pacific
10.4. Latin America
10.5. Middle East & Africa

Chapter 11. North America Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

11.1. North America Bacteriophages Therapy Market– By Targeted Bacteria

11.1.1. Escherichia coli
11.1.2. Staphylococcus
11.1.3. Streptococcus
11.1.4. Pseudomonas
11.1.5. Salmonella
11.1.6. Others

11.2. North America Bacteriophages Therapy Market– By Route of Administration

11.2.1. Oral
11.2.2. Topical
11.2.3. Parenteral

11.3. North America Bacteriophages Therapy Market– By Application

11.3.1. Diagnostic
11.3.2. Antimicrobial Drug Discovery
11.3.3. Veterinary Medicines
11.3.4. Others

11.4. North America Bacteriophages Therapy Market– By End User

11.4.1. Hospitals & Clinics
11.4.2. Academic Research Organizations & Institutes
11.4.3. Others

11.5. North America Bacteriophages Therapy Market– By Country

11.5.1. U.S.
11.5.2. Canada

Chapter 12. Europe Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

12.1. Europe Bacteriophages Therapy Market– By Targeted Bacteria

12.1.1. Escherichia coli
12.1.2. Staphylococcus
12.1.3. Streptococcus
12.1.4. Pseudomonas
12.1.5. Salmonella
12.1.6. Others

12.2. Europe Bacteriophages Therapy Market– By Route of Administration

12.2.1. Oral
12.2.2. Topical
12.2.3. Parenteral

12.3. Europe Bacteriophages Therapy Market– By Application

12.3.1. Diagnostic
12.3.2. Antimicrobial Drug Discovery
12.3.3. Veterinary Medicines
12.3.4. Others

12.4. Europe Bacteriophages Therapy Market– By End User

12.4.1. Hospitals & Clinics
12.4.2. Academic Research Organizations & Institutes
12.4.3. Others

12.5. Europe Bacteriophages Therapy Market– By Country

12.5.1. Germany
12.5.2. France
12.5.3. UK
12.5.4. Spain
12.5.5. Italy
12.5.6. Rest of Europe

Chapter 13. Asia Pacific Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

13.1. Asia Pacific Bacteriophages Therapy Market– By Targeted Bacteria

13.1.1. Escherichia coli
13.1.2. Staphylococcus
13.1.3. Streptococcus
13.1.4. Pseudomonas
13.1.5. Salmonella
13.1.6. Others

13.2. Asia Pacific Bacteriophages Therapy Market– By Route of Administration

13.2.1. Oral
13.2.2. Topical
13.2.3. Parenteral

13.3. Asia Pacific Bacteriophages Therapy Market– By Application

13.3.1. Diagnostic
13.3.2. Antimicrobial Drug Discovery
13.3.3. Veterinary Medicines
13.3.4. Others

13.4. Asia Pacific Bacteriophages Therapy Market– By End User

13.4.1. Hospitals & Clinics
13.4.2. Academic Research Organizations & Institutes
13.4.3. Others

13.5. Asia-Pacific Bacteriophages Therapy Market– By Country

13.5.1. China
13.5.2. India
13.5.3. Japan
13.5.4. South Korea
13.5.5. Rest of Asia-Pacific

Chapter 14. Latin America Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

14.1. Latin America Bacteriophages Therapy Market– By Targeted Bacteria

14.1.1. Escherichia coli
14.1.2. Staphylococcus
14.1.3. Streptococcus
14.1.4. Pseudomonas
14.1.5. Salmonella
14.1.6. Others

14.2. Latin America Bacteriophages Therapy Market– By Route of Administration

14.2.1. Oral
14.2.2. Topical
14.2.3. Parenteral

14.3. Latin America Bacteriophages Therapy Market– By Application

14.3.1. Diagnostic
14.3.2. Antimicrobial Drug Discovery
14.3.3. Veterinary Medicines
14.3.4. Others

14.4. Latin America Bacteriophages Therapy Market– By End User

14.4.1. Hospitals & Clinics
14.4.2. Academic Research Organizations & Institutes
14.4.3. Others

14.5. Latin America Bacteriophages Therapy Market– By Country

14.5.1. Brazil
14.5.2. Mexico
14.5.3. Rest of Latin America

Chapter 15. Middle East & Africa Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

15.1. Middle East & Africa Bacteriophages Therapy Market– By Targeted Bacteria

15.1.1. Escherichia coli
15.1.2. Staphylococcus
15.1.3. Streptococcus
15.1.4. Pseudomonas
15.1.5. Salmonella
15.1.6. Others

15.2. Middle East & Africa Bacteriophages Therapy Market– By Route of Administration

15.2.1. Oral
15.2.2. Topical
15.2.3. Parenteral

15.3. Middle East & Africa Bacteriophages Therapy Market– By Application

15.3.1. Diagnostic
15.3.2. Antimicrobial Drug Discovery
15.3.3. Veterinary Medicines
15.3.4. Others

15.4. Middle East & Africa Bacteriophages Therapy Market– By End User

15.4.1. Hospitals & Clinics
15.4.2. Academic Research Organizations & Institutes
15.4.3. Others

15.5. Middle East & Africa Bacteriophages Therapy Market– By Country

15.5.1. UAE
15.5.2. Saudi Arabia
15.5.3. Turkey
15.5.4. Rest of Middle East & Africa

Chapter 16. Competitive Analysis

16.1. Competition Dashboard
16.2. Company Profiles

16.2.1. Armata Pharmaceuticals, Inc.

16.2.1.1. Company Overview
16.2.1.2. Product Portfolio
16.2.1.3. SWOT Analysis
16.2.1.4. Financial Overview
16.2.1.5. Strategic Overview

16.2.2. Phage International, Inc.

16.2.2.1. Company Overview
16.2.2.2. Product Portfolio
16.2.2.3. SWOT Analysis
16.2.2.4. Financial Overview
16.2.2.5. Strategic Overview

16.2.3. LOCUS BIOSCIENCES, INC.

16.2.3.1. Company Overview
16.2.3.2. Product Portfolio
16.2.3.3. SWOT Analysis
16.2.3.4. Financial Overview
16.2.3.5. Strategic Overview

16.2.4. Pherecydes Pharma

16.2.4.1. Company Overview
16.2.4.2. Product Portfolio
16.2.4.3. SWOT Analysis
16.2.4.4. Financial Overview
16.2.4.5. Strategic Overview

16.2.5. Intralytix, Inc

16.2.5.1. Company Overview
16.2.5.2. Product Portfolio
16.2.5.3. SWOT Analysis
16.2.5.4. Financial Overview
16.2.5.5. Strategic Overview

16.2.6. PhagoMed Biopharma GmbH.

16.2.6.1. Company Overview
16.2.6.2. Product Portfolio
16.2.6.3. SWOT Analysis
16.2.6.4. Financial Overview
16.2.6.5. Strategic Overview

16.2.7. ContraFect Corporation

16.2.7.1. Company Overview
16.2.7.2. Product Portfolio
16.2.7.3. SWOT Analysis
16.2.7.4. Financial Overview
16.2.7.5. Strategic Overview

16.2.8. MICREOS

16.2.8.1. Company Overview
16.2.8.2. Product Portfolio
16.2.8.3. SWOT Analysis
16.2.8.4. Financial Overview
16.2.8.5. Strategic Overview

16.2.9. Phi Therapeutics

16.2.9.1. Company Overview
16.2.9.2. Product Portfolio
16.2.9.3. SWOT Analysis
16.2.9.4. Financial Overview
16.2.9.5. Strategic Overview

16.2.10. BiomX

16.2.10.1. Company Overview
16.2.10.2. Product Portfolio
16.2.10.3. SWOT Analysis
16.2.10.4. Financial Overview
16.2.10.5. Strategic Overview

16.2.11. And Some Other Companies too

Report Description

Market Insights

The bacteriophages therapy market was valued at US$ XX million in 2019 and anticipated to grow at a CAGR of 17.1% throughout the forecast period to reach over US$ XX million by 2028. The rising demand for bacteriophages therapy in the emerging economies owing to the increasing foodborne diseases in the developing economies such as India, China, and others. Moreover, the growing research & development activities worldwide along with the increased mergers & acquisitions and collaborations among key players are the major factors for the growth of the global bacteriophages therapy market over the upcoming years. For instance, in May 2019, Mount Sinai Hospital, New York and Intralytix Inc. collaborated to initiate phase ½ clinical trial to evaluate efficacy of Ecoactive and safety for the patients of inactive Crohn’s disease.

 

Market Trends

The use of bacteriophage therapy for COVID-19 patients is one of the leading trends which are observed in the global bacteriophages therapy market. In November 2020, the Food and Drug Administration (FDA) has given Adaptive Phage Therapeutics a green light to Expanded Access IND to use of phage therapy for COVID19 patients who are in a critical state. Bacterial infections as a result of secondary infection due to COVID19 has left patients facing the battle against antibiotic resistance. The majority of bacteria are those that cause pneumonia and sepsis.

 

Market Drivers

The major factors which are driving the growth of the global bacteriophages therapy market are the growing foodborne diseases along with the increased collaborations among hospitals, research institutes, and major players for the development of bacteriophage therapy. For instance, in June 2020, Intralytix, Inc. announced that the company had entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Soldier Center (CCDC SC) in Natick, Massachusetts. The CRADA will focus on developing a dehydration process for bacteriophage cocktails, for use as a non-chemical and environmentally friendly food safety intervention and mitigation strategy for bacterial pathogens in fresh military procured food items.

 

Market Challenges

 

The bacteriophages therapy market challenges are the high cost of bacteriophage therapy and lack of skilled professionals are anticipated to hinder the market growth in the years to come. Moreover, the expensive testing and high product failure risk for drug development are further anticipated to hamper the market growth.

 

Segment Insights

Based on end-user, the global bacteriophages therapy market is categorized into hospitals and clinics, academic research organizations & institutes and others. In 2019, the hospitals and clinics category accounted for the significant share in the global market. This is majorly due to the increased cases of foodborne diseases worldwide along with the growing investments for advanced healthcare infrastructure across the globe.

 

Regional Insights

North America accounted for the largest share in the global bacteriophages therapy market in 2019 and had over 40% of the market revenue share in the same year. The region had its dominance due to the rising foodborne diseases and the presence of key market players such as Armata Pharmaceuticals, Inc., Phage International, Inc., and iNtODEWORLD, Inc. among others. Moreover, the growing collaborations and mergers among major players is another key factor for the growth of the regional market. Moreover, the U.S. had a major share in the North American bacteriophages therapy market in 2019 and is projected to continue its dominant position worldwide.

 

Besides, Asia Pacific is estimated to witness the fastest growth in the global bacteriophages therapy market in the years to come. This is ascribed to the growing antimicrobial resistance along with the rising foodborne diseases in the region. Furthermore, the increased product launches in Asia Pacific is another key factor for the growth of the market in the region.

 

Top Companies with Recent Development

 

Noticeable players within the Market

 

  • Armata Pharmaceuticals, Inc.,
  • iNtODEWORLD, Inc,
  • Phage International, Inc,
  • Fixed-Phage Limited,
  • LOCUS BIOSCIENCES, INC.,
  • Pherecydes Pharma,
  • Adaptive Phage Therapeutics, Inc.,
  • Intralytix, Phagelux, Inc.,
  • PhagoMed Biopharma GmbH,
  • ContraFect Corporation,
  • MICREOS,
  • Fixed-Phage Limited,
  • Phi Therapeutics.
  • BiomX,
  • Eligo Bioscience,
  • TechnoPhage,
  • Nextbiotics
  • Eliava Bio Preparations LTD

 

The above mentioned major players for the bacteriophages therapy market are investing heavily in Research & Development to introduce new products and offers along with enhanced technology to increase their market share and geographical expansion. Besides, the bacteriophages therapy market players are concentrating on various strategies such as technological innovations, geographical expansion, acquisitions, strategic collaboration, strategic contracts, new product launches, and mergers to increase their market presence. For instance, in January 2021, the first successful attempt at the creation of synthetic bacteriophages was achieved by scientists from the CEB – Centre of Biological Engineering, Universidade Do Minho, Braga in Portugal. The synthetic bacteriophages against Pseudomonas aeruginosa bacteria were created to contain a shortened genome. Researchers hope that this advancement may be the first step in creating a new antibacterial approach to the battle against the constantly evolving antibiotic-resistant threat.

 

Report Scope by Market Segments

 

This report splits the bacteriophages therapy market revenue opportunities worldwide, regional, and national levels and gives a comprehensive research study of the most recent industry activities in each of the sub-segments throughout the forecast period. For the reason of this ponder, Alchemy Market Research has segmented the bacteriophages therapy market report on the premise of product, application, route of administration, end user, and regional analysis:

 

By Targeted Bacteria

  • Escherichia Coli
  • Staphylococcus
  • Streptococcus
  • Pseudomonas
  • Salmonella
  • Others

By Application

  • Diagnostic
  • Antimicrobial Drug Discovery
  • Veterinary Medicines
  • Others

By Route of Administration

  • Oral
  • Topical
  • Parenteral

By End User

  • Hospitals
  • Academic Research Organizations & Institutes
  • Others

Regional Perspective

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia- Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Rest of the Middle East & Africa

This report answers key questions such as

  • What are the challenges in the bacteriophages therapy market?
  • What are the factors anticipated to drive the bacteriophages therapy market?
  • What are trends, restraints, and challenges in the bacteriophages therapy market?
  • Who are the potential customers of the bacteriophages therapy market?
  • Analysis of key strategies by key market players?
  • Which region is growing rapidly?
  • How do rapidly changing consumer perspectives will affect the bacteriophages therapy market?
  • How is the competitive environment?
  • Comprehensive details of factors that will challenge the growth of the market pre & post-COVID-19.
  • How are collaborations evolving in the market?
  • What is the customer sentiment about this market?
  • What are the solutions to the challenges?
  • What are the opportunities in this market?
  • What are the key current & upcoming technological trends estimated to drive the markets?
  • Regions & segment-wise analysis of how various industries will perform?
  • Forecasts on how market drivers, restraints, and future opportunities will affect market dynamics?
Report Synopsis

 Synopsis:

The bacteriophages therapy market is mainly driven by the growing foodborne diseases along with the rising prevalence of others diseases such as obesity, diabetes, cancer, and others. The bacteriophage therapy is also called phage therapy and uses viruses for the treatment of numerous bacterial infections. Moreover, the adoption of bacteriophages therapy for COVID-19 patients along with the growing product launches and acquisitions in the emerging economies are some other key factors for the growth of the global bacteriophages therapy market during the forecast period.  On account of the aforementioned factors, Alchemy Research & Analytics LLP, anticipated that the global bacteriophages therapy market will grow at a CAGR of 17.1% in the years to come.

Table of Content

Chapter 1. Executive Summary

Chapter 2. Market Introduction

Chapter 3. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – Key Industry Dynamics

3.1. Key Market Drivers
3.2. Key Market Restraints
3.3. Market Opportunities
3.4. Future Trends
3.5. Impact Analysis of Drivers and Restraints

Chapter 4. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Market Analysis Tools

4.1. Industry Analysis – Porter’s

4.1.1. Supplier Power
4.1.2. Buyer Power
4.1.3. Substitution Threat
4.1.4. Threat from New Entrants
4.1.5. Competitive Rivalry

4.2. Pestel Analysis

4.2.1. Political Landscape
4.2.2. Environmental Landscape
4.2.3. Social Landscape
4.2.4. Technology Landscape
4.2.5. Legal Landscape

4.3. Major Deals & Strategic Alliances Analysis

4.3.1. Joint Ventures
4.3.2. Mergers and Acquisitions
4.3.3. Licensing and Partnership
4.3.4. Technology Collaborations
4.3.5. Strategic Divestments

Chapter 5. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

Chapter 6. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Targeted Bacteria

6.1. Escherichia coli
6.2. Staphylococcus
6.3. Streptococcus
6.4. Pseudomonas
6.5. Salmonella
6.6. Others

Chapter 7. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Route of Administration

7.1. Oral
7.2. Topical
7.3. Parenteral

Chapter 8. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Application

8.1. Diagnostic
8.2. Antimicrobial Drug Discovery
8.3. Veterinary Medicines
8.4. Others

Chapter 9. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By End User

9.1. Hospitals & Clinics
9.2. Academic Research Organizations & Institutes
9.3. Others

Chapter 10. Global Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028 – By Region

10.1. North America
10.2. Europe
10.3. Asia-Pacific
10.4. Latin America
10.5. Middle East & Africa

Chapter 11. North America Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

11.1. North America Bacteriophages Therapy Market– By Targeted Bacteria

11.1.1. Escherichia coli
11.1.2. Staphylococcus
11.1.3. Streptococcus
11.1.4. Pseudomonas
11.1.5. Salmonella
11.1.6. Others

11.2. North America Bacteriophages Therapy Market– By Route of Administration

11.2.1. Oral
11.2.2. Topical
11.2.3. Parenteral

11.3. North America Bacteriophages Therapy Market– By Application

11.3.1. Diagnostic
11.3.2. Antimicrobial Drug Discovery
11.3.3. Veterinary Medicines
11.3.4. Others

11.4. North America Bacteriophages Therapy Market– By End User

11.4.1. Hospitals & Clinics
11.4.2. Academic Research Organizations & Institutes
11.4.3. Others

11.5. North America Bacteriophages Therapy Market– By Country

11.5.1. U.S.
11.5.2. Canada

Chapter 12. Europe Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

12.1. Europe Bacteriophages Therapy Market– By Targeted Bacteria

12.1.1. Escherichia coli
12.1.2. Staphylococcus
12.1.3. Streptococcus
12.1.4. Pseudomonas
12.1.5. Salmonella
12.1.6. Others

12.2. Europe Bacteriophages Therapy Market– By Route of Administration

12.2.1. Oral
12.2.2. Topical
12.2.3. Parenteral

12.3. Europe Bacteriophages Therapy Market– By Application

12.3.1. Diagnostic
12.3.2. Antimicrobial Drug Discovery
12.3.3. Veterinary Medicines
12.3.4. Others

12.4. Europe Bacteriophages Therapy Market– By End User

12.4.1. Hospitals & Clinics
12.4.2. Academic Research Organizations & Institutes
12.4.3. Others

12.5. Europe Bacteriophages Therapy Market– By Country

12.5.1. Germany
12.5.2. France
12.5.3. UK
12.5.4. Spain
12.5.5. Italy
12.5.6. Rest of Europe

Chapter 13. Asia Pacific Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

13.1. Asia Pacific Bacteriophages Therapy Market– By Targeted Bacteria

13.1.1. Escherichia coli
13.1.2. Staphylococcus
13.1.3. Streptococcus
13.1.4. Pseudomonas
13.1.5. Salmonella
13.1.6. Others

13.2. Asia Pacific Bacteriophages Therapy Market– By Route of Administration

13.2.1. Oral
13.2.2. Topical
13.2.3. Parenteral

13.3. Asia Pacific Bacteriophages Therapy Market– By Application

13.3.1. Diagnostic
13.3.2. Antimicrobial Drug Discovery
13.3.3. Veterinary Medicines
13.3.4. Others

13.4. Asia Pacific Bacteriophages Therapy Market– By End User

13.4.1. Hospitals & Clinics
13.4.2. Academic Research Organizations & Institutes
13.4.3. Others

13.5. Asia-Pacific Bacteriophages Therapy Market– By Country

13.5.1. China
13.5.2. India
13.5.3. Japan
13.5.4. South Korea
13.5.5. Rest of Asia-Pacific

Chapter 14. Latin America Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

14.1. Latin America Bacteriophages Therapy Market– By Targeted Bacteria

14.1.1. Escherichia coli
14.1.2. Staphylococcus
14.1.3. Streptococcus
14.1.4. Pseudomonas
14.1.5. Salmonella
14.1.6. Others

14.2. Latin America Bacteriophages Therapy Market– By Route of Administration

14.2.1. Oral
14.2.2. Topical
14.2.3. Parenteral

14.3. Latin America Bacteriophages Therapy Market– By Application

14.3.1. Diagnostic
14.3.2. Antimicrobial Drug Discovery
14.3.3. Veterinary Medicines
14.3.4. Others

14.4. Latin America Bacteriophages Therapy Market– By End User

14.4.1. Hospitals & Clinics
14.4.2. Academic Research Organizations & Institutes
14.4.3. Others

14.5. Latin America Bacteriophages Therapy Market– By Country

14.5.1. Brazil
14.5.2. Mexico
14.5.3. Rest of Latin America

Chapter 15. Middle East & Africa Bacteriophages Therapy Market– Analysis and Revenue Forecast 2019-2028

15.1. Middle East & Africa Bacteriophages Therapy Market– By Targeted Bacteria

15.1.1. Escherichia coli
15.1.2. Staphylococcus
15.1.3. Streptococcus
15.1.4. Pseudomonas
15.1.5. Salmonella
15.1.6. Others

15.2. Middle East & Africa Bacteriophages Therapy Market– By Route of Administration

15.2.1. Oral
15.2.2. Topical
15.2.3. Parenteral

15.3. Middle East & Africa Bacteriophages Therapy Market– By Application

15.3.1. Diagnostic
15.3.2. Antimicrobial Drug Discovery
15.3.3. Veterinary Medicines
15.3.4. Others

15.4. Middle East & Africa Bacteriophages Therapy Market– By End User

15.4.1. Hospitals & Clinics
15.4.2. Academic Research Organizations & Institutes
15.4.3. Others

15.5. Middle East & Africa Bacteriophages Therapy Market– By Country

15.5.1. UAE
15.5.2. Saudi Arabia
15.5.3. Turkey
15.5.4. Rest of Middle East & Africa

Chapter 16. Competitive Analysis

16.1. Competition Dashboard
16.2. Company Profiles

16.2.1. Armata Pharmaceuticals, Inc.

16.2.1.1. Company Overview
16.2.1.2. Product Portfolio
16.2.1.3. SWOT Analysis
16.2.1.4. Financial Overview
16.2.1.5. Strategic Overview

16.2.2. Phage International, Inc.

16.2.2.1. Company Overview
16.2.2.2. Product Portfolio
16.2.2.3. SWOT Analysis
16.2.2.4. Financial Overview
16.2.2.5. Strategic Overview

16.2.3. LOCUS BIOSCIENCES, INC.

16.2.3.1. Company Overview
16.2.3.2. Product Portfolio
16.2.3.3. SWOT Analysis
16.2.3.4. Financial Overview
16.2.3.5. Strategic Overview

16.2.4. Pherecydes Pharma

16.2.4.1. Company Overview
16.2.4.2. Product Portfolio
16.2.4.3. SWOT Analysis
16.2.4.4. Financial Overview
16.2.4.5. Strategic Overview

16.2.5. Intralytix, Inc

16.2.5.1. Company Overview
16.2.5.2. Product Portfolio
16.2.5.3. SWOT Analysis
16.2.5.4. Financial Overview
16.2.5.5. Strategic Overview

16.2.6. PhagoMed Biopharma GmbH.

16.2.6.1. Company Overview
16.2.6.2. Product Portfolio
16.2.6.3. SWOT Analysis
16.2.6.4. Financial Overview
16.2.6.5. Strategic Overview

16.2.7. ContraFect Corporation

16.2.7.1. Company Overview
16.2.7.2. Product Portfolio
16.2.7.3. SWOT Analysis
16.2.7.4. Financial Overview
16.2.7.5. Strategic Overview

16.2.8. MICREOS

16.2.8.1. Company Overview
16.2.8.2. Product Portfolio
16.2.8.3. SWOT Analysis
16.2.8.4. Financial Overview
16.2.8.5. Strategic Overview

16.2.9. Phi Therapeutics

16.2.9.1. Company Overview
16.2.9.2. Product Portfolio
16.2.9.3. SWOT Analysis
16.2.9.4. Financial Overview
16.2.9.5. Strategic Overview

16.2.10. BiomX

16.2.10.1. Company Overview
16.2.10.2. Product Portfolio
16.2.10.3. SWOT Analysis
16.2.10.4. Financial Overview
16.2.10.5. Strategic Overview

16.2.11. And Some Other Companies too

Report Sample
Report Methodology
Report Customization
Consult the Analyst